1.Decreased Prolidase Activity in Patients with Posttraumatic Stress Disorder.
Süleyman DEMIR ; Mahmut BULUT ; Abdullah ATLI ; Ibrahim KAPLAN ; Mehmet Cemal KAYA ; Yasin BEZ ; Pınar Güzel ÖZDEMIR ; Aytekin SIR
Psychiatry Investigation 2016;13(4):420-426
OBJECTIVE: Many neurochemical systems have been implicated in the development of Posttraumatic Stress Disorder (PTSD). The prolidase enzyme is a cytosolic exopeptidase that detaches proline or hydroxyproline from the carboxyl terminal position of dipeptides. Prolidase has important biological effects, and to date, its role in the etiology of PTSD has not been studied. In the present study, we aimed to evaluate prolidase activity in patients with PTSD. METHODS: The study group consisted of patients who were diagnosed with PTSD after the earthquake that occurred in the province of Van in Turkey in 2011 (n=25); the first control group consisted of patients who experienced the earthquake but did not show PTSD symptoms (n=26) and the second control group consisted of patients who have never been exposed to a traumatic event (n=25). Prolidase activities in the patients and the control groups were determined by the ELISA method using commercial kits. RESULTS: Prolidase activity in the patient group was significantly lower when compared to the control groups. Prolidase activity was also significantly lower in the traumatized healthy subjects compared to the other healthy group (p<0.01). CONCLUSION: The findings of the present study suggest that the decrease in prolidase activity may have neuroprotective effects in patients with PTSD.
Cytosol
;
Dipeptides
;
Earthquakes
;
Enzyme-Linked Immunosorbent Assay
;
Exopeptidases
;
Healthy Volunteers
;
Humans
;
Hydroxyproline
;
Methods
;
Neuroprotective Agents
;
Proline
;
Stress Disorders, Post-Traumatic*
;
Turkey
2.Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment.
Mehmet GÜNEŞ ; Mehmet Akif CAMKURT ; Mahmut BULUT ; Süleyman DEMIR ; Aslıhan Okan IBILOĞLU ; Mehmet Cemal KAYA ; Abdullah ATLI ; Ibrahim KAPLAN ; Aytekin SIR
Clinical Psychopharmacology and Neuroscience 2016;14(4):345-350
OBJECTIVE: Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls. METHODS: We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined anti-psychotics) and 43 healthy controls. RESULTS: MDA levels were higher in schizophrenic patients taking typical antipsychotics compared with healthy controls (p=0.001). ARY levels were higher in patients taking atypical antipsychotics compared with healthy controls (p=0.005). PON1 activity was similar in all groups. CONCLUSION: Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.
Antipsychotic Agents
;
Aryldialkylphosphatase*
;
Humans
;
Lipid Peroxidation
;
Malondialdehyde*
;
Oxidative Stress
;
Schizophrenia*